249 related articles for article (PubMed ID: 31740647)
1. Inherited Retinal Disease Therapies Targeting Precursor Messenger Ribonucleic Acid.
Huang D; Fletcher S; Wilton SD; Palmer N; McLenachan S; Mackey DA; Chen FK
Vision (Basel); 2017 Sep; 1(3):. PubMed ID: 31740647
[TBL] [Abstract][Full Text] [Related]
2. Antisense Oligonucleotide Therapy for Inherited Retinal Dystrophies.
Gerard X; Garanto A; Rozet JM; Collin RW
Adv Exp Med Biol; 2016; 854():517-24. PubMed ID: 26427454
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases.
Xue K; MacLaren RE
Expert Opin Investig Drugs; 2020 Oct; 29(10):1163-1170. PubMed ID: 32741234
[TBL] [Abstract][Full Text] [Related]
4. RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes.
Wilton SD; Fletcher S
Curr Gene Ther; 2011 Aug; 11(4):259-75. PubMed ID: 21453280
[TBL] [Abstract][Full Text] [Related]
5. Design and In Vitro Use of Antisense Oligonucleotides to Correct Pre-mRNA Splicing Defects in Inherited Retinal Dystrophies.
Garanto A; Collin RWJ
Methods Mol Biol; 2018; 1715():61-78. PubMed ID: 29188506
[TBL] [Abstract][Full Text] [Related]
6. Translational development of splice-modifying antisense oligomers.
Fletcher S; Bellgard MI; Price L; Akkari AP; Wilton SD
Expert Opin Biol Ther; 2017 Jan; 17(1):15-30. PubMed ID: 27805416
[TBL] [Abstract][Full Text] [Related]
7. Repair of rhodopsin mRNA by spliceosome-mediated RNA trans-splicing: a new approach for autosomal dominant retinitis pigmentosa.
Berger A; Lorain S; Joséphine C; Desrosiers M; Peccate C; Voit T; Garcia L; Sahel JA; Bemelmans AP
Mol Ther; 2015 May; 23(5):918-930. PubMed ID: 25619725
[TBL] [Abstract][Full Text] [Related]
8. Mutations in HPRP3, a third member of pre-mRNA splicing factor genes, implicated in autosomal dominant retinitis pigmentosa.
Chakarova CF; Hims MM; Bolz H; Abu-Safieh L; Patel RJ; Papaioannou MG; Inglehearn CF; Keen TJ; Willis C; Moore AT; Rosenberg T; Webster AR; Bird AC; Gal A; Hunt D; Vithana EN; Bhattacharya SS
Hum Mol Genet; 2002 Jan; 11(1):87-92. PubMed ID: 11773002
[TBL] [Abstract][Full Text] [Related]
9. The potential of antisense oligonucleotide therapies for inherited childhood lung diseases.
Martinovich KM; Shaw NC; Kicic A; Schultz A; Fletcher S; Wilton SD; Stick SM
Mol Cell Pediatr; 2018 Feb; 5(1):3. PubMed ID: 29411170
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotide-mediated exon skipping of CHRNA1 pre-mRNA as potential therapy for Congenital Myasthenic Syndromes.
Tei S; Ishii HT; Mitsuhashi H; Ishiura S
Biochem Biophys Res Commun; 2015 Jun; 461(3):481-6. PubMed ID: 25888793
[TBL] [Abstract][Full Text] [Related]
11. RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes.
Wilton SD; Fletcher S
Curr Gene Ther; 2005 Oct; 5(5):467-83. PubMed ID: 16250888
[TBL] [Abstract][Full Text] [Related]
12. Splice-switching antisense oligonucleotides as therapeutic drugs.
Havens MA; Hastings ML
Nucleic Acids Res; 2016 Aug; 44(14):6549-63. PubMed ID: 27288447
[TBL] [Abstract][Full Text] [Related]
13. RNA-Based Therapeutic Strategies for Inherited Retinal Dystrophies.
Garanto A
Adv Exp Med Biol; 2019; 1185():71-77. PubMed ID: 31884591
[TBL] [Abstract][Full Text] [Related]
14. Pre-mRNA splicing and retinitis pigmentosa.
Mordes D; Luo X; Kar A; Kuo D; Xu L; Fushimi K; Yu G; Sternberg P; Wu JY
Mol Vis; 2006 Oct; 12():1259-71. PubMed ID: 17110909
[TBL] [Abstract][Full Text] [Related]
15. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
[TBL] [Abstract][Full Text] [Related]
16. Genetic therapies for RNA mis-splicing diseases.
Hammond SM; Wood MJ
Trends Genet; 2011 May; 27(5):196-205. PubMed ID: 21497936
[TBL] [Abstract][Full Text] [Related]
17. Targeting RNA splicing for disease therapy.
Havens MA; Duelli DM; Hastings ML
Wiley Interdiscip Rev RNA; 2013; 4(3):247-66. PubMed ID: 23512601
[TBL] [Abstract][Full Text] [Related]
18. Developing Cell-Based Therapies for RPE-Associated Degenerative Eye Diseases.
Ben M'Barek K; Habeler W; Regent F; Monville C
Adv Exp Med Biol; 2019; 1186():55-97. PubMed ID: 31654386
[TBL] [Abstract][Full Text] [Related]
19. Regulation of pre-mRNA splicing by antisense oligonucleotides.
Taylor JK; Dean NM
Curr Opin Drug Discov Devel; 1999 Mar; 2(2):147-51. PubMed ID: 19649941
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the functional impact on the pre-mRNA splicing process of 28 nucleotide variants associated with Pompe disease in GAA exon 2 and their recovery using antisense technology.
Goina E; Musco L; Dardis A; Buratti E
Hum Mutat; 2019 Nov; 40(11):2121-2130. PubMed ID: 31301153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
